Melanotan 2: Non-Selective, Unstudied in Late Trials, Not Approved

The short version

Melanotan 2 is a synthetic cyclic peptide structurally related to PT-141, developed from the same natural hormone template (alpha-MSH), but with two key differences: it ends with an amide group instead of a carboxylic acid, and its receptor activity is non-selective — it activates all five melanocortin receptor subtypes (MC1R through MC5R) rather than targeting MC4R alone. That non-selectivity explains why using it produces a skin tan (MC1R on melanocytes), a rise in sexual interest and erections (MC4R in the hypothalamus), and reduced appetite (MC3R/MC4R in the mesolimbic brain) all at once.

Melanotan 2 has never been approved for any use by the FDA or any other major regulator. No Phase 2 or Phase 3 clinical trials have been completed. All controlled human data come from small Phase 1 studies — the most cited includes 10 men ^[12]. Regulators including the FDA, the UK's MHRA, Australia's TGA, and Ireland's HPRA have issued specific warnings against tanning products containing melanotan. It carries a documented, serious adverse-event record. This page covers all of that honestly, including what people in research-use communities report experiencing.

What it is

Melanotan 2 is a cyclic (lactam-bridged) heptapeptide with the sequence Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH2. That sequence is a truncated, cyclized, D-phenylalanine-substituted derivative of the core active fragment of alpha-MSH, designed at the University of Arizona in the late 1980s for superpotent, enzymatically resistant melanotropic activity ^[11].

Three important distinctions this desk maintains throughout:

1. Melanotan 2 is not the same as afamelanotide (also known as Melanotan I). Afamelanotide is a separate, linear analog that has been approved for the rare condition erythropoietic protoporphyria. Its approval and safety data do not extend to Melanotan 2 ^[11].
2. Melanotan 2 is not bremelanotide (PT-141). They share the same peptide backbone and both derive from alpha-MSH, but they differ in the terminal chemistry and therefore in receptor selectivity, pharmacology, regulatory status, and safety profile. PT-141's selective MC4R focus was deliberately engineered by modifying Melanotan 2 ^[11].
3. Melanotan 2 is always written as two words here — Melanotan 2 — to avoid confusion with other compounds in the naming landscape.

How it works

Melanotan 2 is a non-selective agonist at all five melanocortin receptors (MC1R, MC2R, MC3R, MC4R, MC5R) ^[11]. Each receptor drives different biology:

• MC1R (on melanocytes in the skin): raises intracellular cAMP, activates the PKA-CREB-MITF signaling cascade, upregulates the enzyme tyrosinase, and shifts pigment production toward dark eumelanin — producing skin and hair darkening even without UV exposure.
• MC4R (in hypothalamus, mesolimbic brain): the same receptor PT-141 targets selectively. Activation drives sexual motivation, arousal, and erectile function. In a landmark 1998 double-blind, placebo-controlled crossover study of 10 men with psychogenic erectile dysfunction, subcutaneous Melanotan 2 produced clinically apparent erections in 8 of 10 men, with mean >80% tip rigidity lasting 38.0 minutes versus 3.0 minutes for placebo (p=0.0045), alongside transient nausea, stretching, and yawning ^[12].
• MC3R (mesolimbic circuits): nucleus-accumbens MC3R/MC4R activation reduces food intake and appetite. In mice, Melanotan 2 microinjected into the nucleus accumbens significantly decreased food consumption and appetitive responding without producing conditioned taste aversion or changing metabolic rate ^[9] — meaning the appetite reduction appears motivational rather than aversive or metabolic.
• MC5R (exocrine and sebaceous glands): less studied in humans; involved in gland secretion.

This non-selectivity is the origin of both its appeal (tanning and sexual effects simultaneously) and its safety concerns (a broader range of off-target effects than the selective compound PT-141).

What the research shows

Erectile function (the primary human controlled trial). In a 1998 double-blind, placebo-controlled crossover study (n=10 men with psychogenic erectile dysfunction), subcutaneous Melanotan 2 produced clinically apparent erections in 8 of 10 men, with mean >80%-rigidity duration of 38.0 vs. 3.0 minutes (p=0.0045) ^[12]. Transient nausea, stretching, and yawning were reported but required no treatment. This is the most cited controlled human finding. No Phase 2 or 3 trial followed for any indication.

Appetite / mesolimbic signaling. In male C57BL/6J mice, bilateral nucleus accumbens microinjection of Melanotan 2 (0.1-1 nmol/side) significantly decreased both home-cage food consumption and operant food-seeking, without producing conditioned taste aversion or a change in metabolic rate ^[9]. The result implicates mesolimbic (reward-circuit) MC3R/MC4R in the appetite reduction, suggesting it is about motivation, not aversion.

Oral mucosal pigmentation (case report, 2026). A man who self-administered Melanotan 2 for 64 days developed brown pigmentation on the attached gingiva and buccal mucosa of both jaws. Buccal pigmentation began to fade by 28 days after stopping; gingival pigmentation persisted at reduced intensity at 3 months ^[8]. This is one of the most recent published Melanotan 2 safety reports and directly illustrates the MC1R-driven mucosal pigmentation risk.

Renal infarction (case report and review, 2020). A case report with literature review describes renal infarction most likely attributable to Melanotan 2 injection, with the authors noting prior descriptions of Melanotan 2-associated rhabdomyolysis and renal failure, and proposing both thrombotic and direct-toxic renal mechanisms ^[10].

Historical review. The 2006 review of melanocortin peptide therapeutics documents the MT-I / Melanotan 2 / PT-141 lineage — Melanotan 2 was patented and tested clinically for male erectile dysfunction, while the separately derived PT-141 analog advanced toward commercialization ^[11]. Melanotan 2 did not complete pivotal trials for any indication.

Reported effects, cautions & safety

The following reported effects are drawn from people in research-use communities. They are anecdotal, not clinical evidence, presented because this record is part of what is known about how this compound behaves in real-world use. Melanotan 2's adverse-event record is documented not only in forum accounts but in published case reports and regulatory warnings.

Reported benefits (anecdotal):

• Rapid, deep tan with little or no sun: Consistently described as the main reason people seek it — skin darkening within days, a deeper color with far less UV than they could otherwise achieve.
• Increased libido and spontaneous erections (men): Men frequently report a sudden surge in sexual interest and unprompted erections, sometimes hours after injecting and at inconvenient times.
• Reduced appetite: Many users report feeling substantially less hungry, sometimes from the first dose. Some welcome this; others find it unwanted.
• Cosmetic confidence: Many users describe feeling more attractive with the tan and cite this as why they continue despite side effects.

Reported adverse effects (anecdotal and case-report-confirmed):

• Nausea (and sometimes vomiting): One of the most consistently described effects, hitting shortly after injecting and easing over hours. Strongest when starting out.
• Facial flushing and feeling hot: Face going red, warm, and flushed within minutes to an hour of injecting — usually short-lived.
• Spontaneous stretching and yawning: A distinctive and very commonly mentioned sensation in the period after injecting, often alongside flushing and nausea.
• Darkening of existing moles and freckles: Frequently the first visible sign of activity — existing moles and freckles getting noticeably darker, often before an overall tan develops.
• Appearance of new moles: A frequent and alarming report among longer-term users — new moles appearing, sometimes many at once, sometimes within days of a dose.
• Darkening of face, lips, scars, and genital skin: Selective darkening of the lips, gums, old scars, and underarm skin beyond an overall tan.
• Uneven, blotchy, or unnaturally long-lasting tan: Many users describe color coming in patchy or mottled, persisting for weeks to months after stopping.
• Fatigue and 'melanotan flu': Run-down, flu-like tiredness in the first days of use, usually fading with continued use.
• Darkening that fades unevenly after stopping: Moles and freckles sometimes staying darker than before cessation.

Serious clinical safety cautions:

• New, changing, or darkening moles and melanoma risk: As a non-selective MC1R agonist, Melanotan 2 drives melanocyte activity throughout the skin. Case reports document eruptive new nevi, dysplastic nevi, and melanoma arising in users. Any new or changing mole during or after use warrants prompt dermatological assessment ^[10][11].
• Rhabdomyolysis and acute kidney injury: A published case links Melanotan 2 injection to rhabdomyolysis (severe muscle breakdown) and a separate case-and-review describes renal infarction, with proposed thrombotic and direct-toxic mechanisms ^[10].
• Priapism (prolonged, painful erection): Several case reports describe priapism following Melanotan 2 use, including after apparent overdose. Priapism is a urological emergency that can cause permanent tissue damage if untreated.
• Posterior reversible encephalopathy syndrome (PRES): A case report documents PRES — a neurological condition with brain swelling, headache, seizures, and visual disturbance — in association with Melanotan 2 use, consistent with its cardiovascular and blood-pressure effects.
• Nausea and blood-pressure effects: Preclinical work on alpha-MSH analogs demonstrates pressor (blood-pressure-raising) effects that can be worsened by impaired nitric oxide signaling ^[11].
• Unregulated supply — contamination, mislabeling: Analytical studies of Melanotan products bought online repeatedly find inaccurate labeling, variable peptide content, and impurities. A buyer has no way to verify actual identity, dose, purity, or sterility ^[11].
• No regulatory approval, unknown long-term safety: Melanotan 2 has never been approved by any major regulator. Regulators including the US FDA, UK MHRA, Australia's TGA, and Ireland's HPRA have issued explicit warnings against tanning products containing melanotan.
• Not the same as approved melanocortin drugs: The safety data for afamelanotide and for bremelanotide (PT-141) do not extend to Melanotan 2, which is a different, unapproved compound. These should not be confused ^[11].

Where it fits in the melanocortin research picture

Melanotan 2 is the wider-acting, less-selective, and more hazardous compound on this desk. Where PT-141 was specifically engineered from Melanotan 2 to retain MC4R arousal activity while reducing pigmentation, Melanotan 2 does everything — tan, appetite, sexual function — but with a broader adverse-event footprint, no completed late-phase trials for any indication, and no regulatory approval anywhere ^[11]. Its controlled human evidence base is a single 10-person study from 1998 ^[12].

The historical arc is instructive: Melanotan 2 was the intermediate step in a research program that went on to produce PT-141 specifically because the non-selective compound's safety and selectivity profile was insufficient for drug development. That history is not a reason to dismiss Melanotan 2's pharmacology — the melanocortin effects are real — but it is a reason to read its safety record with care. See the comparison page for a direct side-by-side.